ARTICLE: "Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment," by KM Daddario-DiCaprio et al. The Lancet DOI: 10.1016/S0140-6736(06)68546-2 (2006). This study was conducted by scientists at the Uniformed Services University of Health Sciences; the U.S. Army Medical Research Institute of Infectious Diseases; the Public Health Agency of Canada; the University of Manitoba; and the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health.
SPOKESPERSON: Peter B. Jahrling, Ph.D., Chief Scientist, NIAID Integrated Research Facility at Fort Detrick in Frederick, Maryland, is available to comment on the study's findings.
CONTACT: To schedule interviews, contact Jason Bardi in the NIAID Media and Public Information Branch, (301) 402-1663, firstname.lastname@example.org.
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.
The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.
News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.